Author: PAREXEL International
Edition: 1
Publisher: Parexel Intl Corp
Binding: Hardcover
ISBN: 1882615972
PAREXEL Biopharmaceutical Statistical Sourcebook 2012/2013 (Pharmaceutical R & D Statistical Sourcebook)
The PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2012/2013 is the leading resource for statistics, trends, and proprietary market intelligence and analysis on the biopharmaceutical industry. Medical books PAREXEL Biopharmaceutical Statistical Sourcebook 2012/2013 . Supported by thousands of graphs, illustrations, and analysis, the Sourcebook provides the latest market intelligence on every aspect of biopharmaceutical development from product discovery, to R&D performance and productivity, to time-to-market trends. With key analysis and contributions from leading consultancies and experts, the Sourcebook provides real-world data and analysis, including: * A record number of all-new metrics on drug development costs and complexity. * New proprietary analyses on US clinical trial starts, segmented by therapeutic category, as well as overall active clinical trials. * Emerging data on worldwide and company-specific R&D pipelines, strategies, and product launch trends Medical books .
Download link for Parexel Biopharmaceutical Statistical Sourcebook 2012/2013
Medical Book PAREXEL Biopharmaceutical Statistical Sourcebook 2012/2013
Supported by thousands of graphs, illustrations, and analysis, the Sourcebook provides the latest market intelligence on every aspect of biopharmaceutical development from product discovery, to R&D performance and productivity, to time-to-market trends. With key analysis and contributions from leading consultancies and experts, the Sourcebook provides real-world data and analysis, including: * A record number of all-new metrics on drug development costs and complexity. * New proprietary analyses on US clinical trial starts, segmented by therapeutic category, as well as overall active clinical trials. * Emerging data on worldwide and company-specific R&D pipelines, strategies, and product launch trends. * New analyses on emerging trends in pharma and biotech licensing deals and other partnerships critical to industry's efforts. * Drug approval statistics compiled from FDA, EMEA, and other regulatory agencies. * New global R&D spending trends and other international R&D data from key markets. * International statistics on drug development output. * And much more! Plus, NEW in the 2012/2013 edition: * An all-new 2012 analysis on the current share of clinical trial spending by region for 2011. * All-new studies on the emerging clinical trial markets in India, China, Korea, Canada, and dozens of other key markets and regions. * All-new analyses and actual/projected metrics on the biosimilars market. * A series of new "dashboards" on costs by phase of development, R&D attrition rates, product development times, and other areas. * Forecasting models on biopharma sales, R&D spending, the pharma/biotech markets, and other meaningful industry metrics. The PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2012/2013 is a must-have resource for the drug development industry. It is an invaluable resource for executives and managers working in the pharma and biotech industries. The Sourcebook puts real-world data sets at your fingertips for presentations, reports, business development efforts, strategic meetings, and critical decision-making analyses.
